Financing
Proceeds From Issuance Of Common Stock From At The Market Offering
Over 3 years (FY 2021 to FY 2024), Proceeds From Issuance Of Common Stock From At The Market Offering shows an upward trend with a 127.4% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026May 6, 2026
How to read this metric
Higher proceeds indicate active use of ATM facilities to bolster cash reserves, often signaling a need for operational funding.
Detailed definition
This metric measures cash proceeds from 'at-the-market' (ATM) equity offerings, where shares are sold directly into the...
Peer comparison
Widely used by biotech companies to maintain liquidity without the volatility of large, discrete public offerings.
Metric ID:
financing_proceeds_from_issuance_of_common_stock_from_at_233216Historical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.52M | $2.52M | $2.52M | $12.48M | $12.48M | $12.48M | $12.48M | $15.51M | $15.51M | $15.51M | $15.51M | $29.68M | $29.68M | $29.68M | $29.68M | $0.00 | $226.73M |
| QoQ Change | — | +0.0% | +0.0% | +394.4% | +0.0% | +0.0% | +0.0% | +24.3% | +0.0% | +0.0% | +0.0% | +91.3% | +0.0% | +0.0% | +0.0% | -100.0% | — |
| YoY Change | — | — | — | — | +394.4% | +394.4% | +394.4% | +24.3% | +24.3% | +24.3% | +24.3% | +91.3% | +91.3% | +91.3% | +91.3% | -100.0% | — |
Range$0.00 – $226.73M
CAGR+207.9%
Avg YoY Growth+128.8%
Median YoY Growth+91.3%
Proceeds From Issuance Of Common Stock From At The Market Offering at Other Companies
Frequently Asked Questions
- What is Revolution Medicines, Inc.'s proceeds from issuance of common stock from at the market offering?
- Revolution Medicines, Inc. (RVMD) reported proceeds from issuance of common stock from at the market offering of $226.73M in Q1 2026.
- What is the long-term trend for Revolution Medicines, Inc.'s proceeds from issuance of common stock from at the market offering?
- Over 3 years (2021 to 2024), Revolution Medicines, Inc.'s proceeds from issuance of common stock from at the market offering has grown at a 127.4% compound annual growth rate (CAGR), from $10.10M to $118.73M.
- What does proceeds from issuance of common stock from at the market offering mean?
- Cash raised by selling shares gradually into the open market at current prices.